Search

Reprioritization of Global Fund Programs: What it means  for Community actors in Malaria, Tuberculosis and HIV

AVAC Responds to Government’s Emergency Appeal to SCOTUS

In response to the US government’s August 26 emergency application to the US Supreme Court seeking to stay the preliminary injunction in the AVAC v Department of State legal case against the foreign aid freeze, AVAC’s Executive Director, Mitchell Warren, asks whether SCOTUS will restore some of the checks and balances this administration is consistently undermining.

AVAC Responds to Government’s Emergency Appeal to SCOTUS

In response to the US government’s August 26 emergency application to the US Supreme Court seeking to stay the preliminary injunction in the AVAC v Department of State legal case against the foreign aid freeze, AVAC’s Executive Director, Mitchell Warren, asks whether SCOTUS will restore some of the checks and balances this administration is consistently undermining.

IMPT LET’s Talk MPTs “Introducing the Dual Prevention Pill: Lessons Learned and What’s Next for Regulatory, Research, and Rollout” Webinar

The EXPrESSIVE Trials Test a Monthly Pill for PrEP: Advocates speak

The drug maker Merck’s recent announcement of two new efficacy trials of a monthly PrEP pill, known as the EXPrESSIVE program, is welcome news. In addition, Merck’s robust commitment to stakeholder engagement to date contributes an important model of Good Participatory Practice (GPP) to the field, by putting global advocates at the forefront of planning for the program.

Key Messages from IAS 2025

Global Health Watch: Pullback at UNGA, foreign aid freeze litigation, FY26 budget cuts and new NIH research priorities

This week brought another round of threats and attacks on US global health policy including troubling court rulings over the foreign aid freeze, deepening cuts to the fiscal year 2026 (FY26) global health budget, and troubling developments at NIH, where new research priorities and another agency-wide review could disrupt HIV and global health research. We also track new signals of a US pullback at UN General Assembly (UNGA).

Global Advocates Welcome the Launch of Merck’s EXPrESSIVE Program

Known as the EXPrESSIVE program, the drug maker Merck has two trials testing a monthly pill for PrEP. Merck is committed to stakeholder engagement, putting global advocates at the forefront of planning for the program. Numerous organizations and advocates commend Merck’s dedication to hearing from the community and shared this statement.

Next Up: A monthly pill for PrEP? 

This episode features Merck Distinguished Scientist Rebeca Plank and AVAC’s Regional Manager for Research Engagement Grace Kumwenda. They explain why a monthly pill could be so important to HIV prevention and how GPP is shaping the design and rollout of the trials.

Global Health Watch: NIH swings to implementation science, Court upholds foreign aid freeze, federal grants politicized & violence at US CDC

This issue covers the Appeals Court opinion in AVAC v Department of State, a violent attack on the CDC fueled by vaccine disinformation, the continued dismantling of the NIH with a potential pendulum swing toward implementation science and away from basic science and clinical research, and a new executive order politicizing federal grants.